VectivBio Holding a clinical-stage biopharmaceutical company, has announced a combined gross proceeds from public offering and private sale of USD 50 million. On one side, the company has announced the pricing of a follow-on public offering
Tags :VectivBio
Homburger advises VectivBio on USD 110 m crossover financing.The team was led by partner Andreas Müller (pictured left). Walder Wyss advised BPI France, Cowen Healthcare Investments, Novo Ventures, OrbiMed and Versant Ventures as lead